Clinical trials: Glioblastoma Multiform
High Grade Brain Tumor
Histopathologic Evaluation of High Grade Brain Tumors by High Order Diffusion Tensor Imaging
This study will examine the use of a variation of standard magnetic resonance imaging (MRI) called diffusion tensor MRI (DT-MRI), in order to evaluate the peripheral white matter infiltration of high grade brain tumors.
- Trial name
- TeDi-C2 (NCT01699269)
- Testing
- peritumoral glial cell infiltration
- Where
- France
- Volunteers
- 10 people
- Sponsor
- University Hospital, Clermont-Ferrand
Glioma, Glioblastoma Multiforme
Study of DC Vaccination Against Glioblastoma
This is a Phase II study in a single center to determine the efficacy of autologous dendritic cells (DCs) loaded with autogeneic glioma stem-like cells (A2B5+) administered as a vaccination in adults with glioblastoma multiforme…
- Conditions
- Glioma, Glioblastoma Multiforme, Neoplasms
- Trial name
- NCT01567202
- Testing
- Surgery, Chemotherapy, Radiotherapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Huashan Hospital
Glioblastoma
Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform
This study is a phase I, open label trial to determine the Maximum Tolerated Dose (MTD), safety, pharmacokinetics, and efficacy of BIBW 2992 (an epidermal growth factor receptor(EGFR)inhibitor) to be used in combination with…
- Trial name
- NCT00977431
- Testing
- Temozolomide, Radiotherapy, BIBW2992
- Where
- 5 sites in United Kingdom
- Volunteers
- 36 people
- Sponsor
- Boehringer Ingelheim
Glioblastoma Multiforme (GBM), Glioblastoma Multiform (Grade IV Astrocytoma)
5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours
The purpose of this clinical trial is to evaluate the safety and tolerability of avutometinib and defactinib and to determine the preliminary antitumour activity of avutometinib and defactinib administered at the recommended…
- Conditions
- Glioblastoma Multiforme (GBM), Glioblastoma Multiform (Grade IV Astrocytoma), Diffuse Hemispheric Glioma, H3 G34-Mutant, Malignant Primary Gliomas
- Trial name
- 5G-RUBY (NCT06630260)
- Testing
- Avutometinib, Defactinib, Temozolomide
- Where
- 3 sites in United Kingdom
- Volunteers
- 182 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Neoplastic Disease, Glioblastoma
Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma
This global clinical trial which evaluates the efficacy and safety of TLX101-Tx, an investigational radiopharmaceutical therapy, in combination with lomustine versus lomustine alone in adult patients with first recurrence of…
- Conditions
- Neoplastic Disease, Glioblastoma, Glioblastoma (GBM), Glioblastoma Multiform
- Trial name
- IPAX BrIGHT (NCT07100730)
- Testing
- TLX-101-Tx + Lomustine, TLX101-Tx
- Where
- 9 sites in Australia, Austria and 2 more
- Volunteers
- 50 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Glioma
Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment
This is an open-label, multicenter, Phase 1 study to establish the safety and efficacy/tolerability of a single dose of 186RNL by the intraventricular route (via intraventricular catheter) for recurrence glioma in patients who…
- Trial name
- NCT05460507
- Testing
- Retreatment Rhenium Liposome
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Cerenome
Glioblastoma
Combining Radiotherapy and Temozolomide With Dichloroacetate in Patients With Newly Diagnosed Glioblastoma
This is a study to see whether radiotherapy plus chemotherapy (Temozolomide) plus Dichloroacetate (DCA) improves overall survival and offers better control of the disease in patients with newly diagnosed Glioblastoma Multiforme…
- Trial name
- NCT00703859
- Testing
- Dichloroacetate (DCA)
- Sponsor
- AHS Cancer Control Alberta
Glioblastoma, Gliosarcoma
Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas
Objectives: To determine the maximum tolerated dose of oral topotecan when administered with Temodar to patients with malignant glioma To characterize any toxicity associated with the combination oral topotecan and Temodar.
- Conditions
- Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma
- Trial name
- NCT00610571
- Testing
- Oral Topotecan and Temodar
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Katy Peters
Glioblastoma Multiforme (GBM), Pancreatic Ductal Adenocarcinoma (PDAC)
Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC)
The goal of this Phase I clinical trial is to evaluate how the imaging drug 203Pb- RMX-VH-PIB distributes in the body and how much radiation different organs receive in patients with glioblastoma multiforme (GBM) or pancreatic…
- Trial name
- RMX-VH (NCT07733674)
- Testing
- 203Pb-RMX-VHPIB injection, SPECT/CT Imaging
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Radiomedix, Inc.
Glioblastoma, Cancer of Brain and Nervous System
Phase 1-2 of Temozolomide and Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform
The purpose of this study is to investigate the safety and effectiveness of a combination treatment for glioblastoma multiforme utilizing radiotherapy plus the FDA-approved chemotherapy drug temozolomide
- Conditions
- Glioblastoma, Cancer of Brain and Nervous System, Glioblastoma Multiforme
- Trial name
- Tx-Treatment (NCT01120639)
- Testing
- Temozolomide, Stereotactic Radiosurgery (SRS)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stanford University
Caregiver, Glioblastoma Multiform (Grade IV Astrocytoma)
A Supportive Group Intervention for Caregivers to Patients Diagnosed With a Glioblastoma
Feasibility test and evaluation of a group intervention for caregivers to patients diagnosed with a glioblastoma.
- Trial name
- SUGRI (NCT06869577)
- Testing
- Project SUGRI: A supportive group intervention for caregivers to patients with a glioblastoma
- Where
- Denmark
- Volunteers
- 24 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Glioblastoma Multiform, Recurrent Glioblastoma
Nk Cell Therapy for Recurrent Glioblastoma Multiform Patients
Glioblastoma multiform is one of the most invasive and deadly cancers that progresses rapidly and leads to death. Surgery with radiotherapy /chemotherapy, as a treatment approach is ineffective in some cases and is associated…
- Trial name
- NCT05108012
- Testing
- NK cell therapy
- Where
- Iran
- Volunteers
- 5 people
- Sponsor
- Royan Institute
Glioma
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
This is a multi-center, sequential cohort, open-label, volume and dose escalation study of the safety, tolerability, and distribution of 186RNL given by convection enhanced delivery to patients with recurrent or progressive…
- Trial name
- NCT01906385
- Testing
- Rhenium Liposome Treatment
- Where
- 4 sites in United States
- Volunteers
- 55 people
- Sponsor
- Cerenome
Malignant Primary Gliomas, Glioblastoma Multiform (Grade IV Astrocytoma)
5G-EMERALD: Amivantamab in Malignant Brain Tumours
The purpose of this clinical trial is to evaluate the safety and tolerability of amivantamab and to determine the preliminary antitumour activity of amivantamab administered at the recommended Phase 2 dose (RP2D).
- Conditions
- Malignant Primary Gliomas, Glioblastoma Multiform (Grade IV Astrocytoma), Diffuse Hemispheric Glioma, H3 G34-Mutant, Glioblastoma Multiforme (GBM)
- Trial name
- 5G-EMERALD (NCT06632236)
- Testing
- Amivantamab
- Where
- 2 sites in United Kingdom
- Volunteers
- 12 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Glioblastoma Multiforme
Disulfiram/Copper Combination In The Treatment of Newly Diagnosed Glioblastoma Multiform
Glioblastoma multiform (GBM) is the most common malignant primary brain tumor in adults. Despite maximal treatment tumor relapse occurs regularly accompanied by unfavourable prognosis.
- Trial name
- GLIODIS (NCT01777919)
- Testing
- Temozolomide, Disulfiram, Copper
- Where
- Greece
- Volunteers
- 32 people
- Sponsor
- Olympion Medical Center
Glioblastoma Multiform (Grade IV Astrocytoma)
Dose Evaluation Safety STudy IN Individuals With Astrocytoma Taking PolyMVA
In order to test the investigators hypothesis that 8 teaspoons of POLYMVA is safe in a population of patients with grade IV brain astrocytoma (glioblastoma multiforme), the investigators will conduct an open-label, prospective…
- Trial name
- DESSTINI_A (NCT01833273)
- Testing
- PolyMVA
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Stony Brook University